IONS

Business Context and Reporting Period

Company: Isis Pharmaceuticals, Inc. (Note: Filing text refers to the registrant as Isis Pharmaceuticals, Inc., though the request metadata mentions Ionis Pharmaceuticals, Inc.)
Reporting Period: Quarterly period ended March 31, 2007 (Form 10-Q).
Business Overview: A biopharmaceutical company pioneering antisense drug technology and the Ibis T5000 Biosensor System for infectious disease identification. The company operates two primary segments: Drug Discovery and Development, and Ibis Biosciences.

Key Financial Metrics

Note: Cash balances include funds held by the consolidated variable interest entity, Symphony GenIsis, Inc.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 51% to $2.45 million, driven by lower collaboration revenue and timing differences in Ibis Biosciences government contract revenue. A one-time $750,000 milestone from Eli Lilly in Q1 2006 is not present in Q1 2007.
• Improved Net Loss: Net loss applicable to common stock improved by $4.46 million. This improvement was primarily due to a $6.8 million benefit attributed to the noncontrolling interest in Symphony GenIsis, Inc., partially offset by increased operating expenses and a $1.2 million loss on early debt retirement.
• Debt Restructuring: In January 2007, the company issued $162.5 million in 2 5/8% convertible notes due 2027. Proceeds were used to repurchase $44.2 million of its 5 1/2% notes due 2009. The remaining $80.8 million of the 5 1/2% notes was classified as a current liability due to a planned May 2007 redemption.
• Investment Gains: The company recognized a $1.52 million gain on the sale of a portion of its Alnylam Pharmaceuticals equity securities.

Guidance, Outlook, and Risks

• Outlook: Management believes current resources are sufficient to meet anticipated requirements through at least the middle of 2010. The new debt issuance reduces annual cash interest payments by approximately $2.6 million.
• New Collaboration: In May 2007, Isis entered a collaboration with Bristol-Myers Squibb (BMS) targeting PCSK9. The deal includes a $15 million upfront fee and at least $9 million in research funding over three years, expected to generate approximately $8 million in annual revenue.
• Clinical Progress: Positive Phase 2 results were reported for ISIS 301012 (cholesterol-lowering drug), showing dose-dependent reductions in LDL-C. Pivotal trials are planned for later in 2007.
• Risks:
  • Profitability: The company has accumulated losses of approximately $829.8 million and expects to incur additional operating losses.
  • Government Dependence: Approximately 64% of revenue is derived from U.S. government agencies, which can terminate contracts at their convenience.
  • Development Risk: High failure rate in drug development; previous Phase 3 failures (Affinitak, alicaforsen) highlight the risk of future clinical trials.
  • Debt Obligations: Significant debt maturities and the potential dilution from convertible notes.

Investor Verification Checklist

• Debt Redemption Timing: Verify the execution and financial impact of the May 2007 redemption of the remaining $80.8 million of 5 1/2% notes.
• Revenue Recognition: Review the amortization schedule for the new BMS collaboration ($15M upfront) and the timing of Ibis commercial revenue recognition.
• Cash Burn Rate: Assess the sustainability of the $20.8 million operating cash outflow in Q1 2007 against the $285.6 million cash/investment balance.
• Symphony GenIsis Option: Evaluate the financial implications of the option to reacquire the apoB-100, GCGR, and GCCR programs from Symphony GenIsis, including the potential cash or stock payment required.
• Government Contract Stability: Monitor the status of U.S. government contracts, which represent the majority of Ibis Biosciences revenue.